Dosing Sandostatin^® LAR^® for Acromegaly

Dosing^1*

• The recommended initial dosing of Sandostatin^® LAR^® is 20 mg administered at 4-week intervals for 3 months
• Subsequent dosage adjustment should be based on
  • GH and IGF-1 concentrations
  • Clinical symptoms

For patients currently receiving s.c. Sandostatin^® Injection

• The initial dose of Sandostatin^® LAR^® can be given the day after the last dose of s.c. Sandostatin^®

Managing Sandostatin^® LAR^® dosing over time¹

For patients uncontrolled on Sandostatin^® LAR^®

• Patients whose GH and IGF-1 levels are not controlled within 3 months
  • Dose may be increased to 30 mg every 4 weeks

• If after 3 months, GH, IGF-1, and/or symptoms are not adequately controlled at a dose of 30 mg
  • Dose may be increased to 40 mg every 4 weeks

For patients consistently controlled on Sandostatin^® LAR^®

• Patients whose GH is consistently <1 µg/L and IGF-1 is normalized and in whom most reversible signs/symptoms of acromegaly have disappeared after 3 months of treatment with 20 mg
  • Dose may be decreased to 10 mg every 4 weeks
  • However, particularly in this group of patients, it is recommended to closely monitor adequate control of serum GH and IGF-1 concentrations, and clinical signs/symptoms at this low dose of Sandostatin^® LAR^®
• For patients on a stable dose of Sandostatin^® LAR^®, assessment of GH and IGF-1 should be made every 6 months

*The dosing information on this page applies only to patients prescribed Sandostatin^® LAR^® for acromegaly.

Reference:
1. Sandostatin^® LAR^® Summary of Product Characteristics. Novartis Pharma AG. 2018.

Please see the Summary of Product Characteristics.